Conjugated nitro alkene anticancer agents based on isoprenoid metabolism
US7312191B2 · kind B2 · utility
29Cited by
2References
6Claims
0Family size
Assignee
Inventors
Key dates
| Filing date | Jul 29, 2004 |
| Grant date | Dec 25, 2007 |
| Priority date | — |
| Expiry date | Jul 29, 2024 |
Classification
- Technology area (CPC C)Chemistry; Metallurgy
- CPC primaryC07C211/52
- WIPO fieldOrganic fine chemistry
- WIPO sectorChemistry
Abstract
Conjugated nitro alkene compounds hamper or prevent proliferation of cancer cells in cell culture and in cancer patients, which can result in a decrease in tumor size and/or disappearance of the cancer. The compounds may act by interference with cancer cell biochemistry, in which isoprenoid groups such as farnesyl and geranylgeranyl become bonded to various oncogenic proteins such as Ras, RhoA, RhoB, or some other growth-related cellular protein(s).
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.